Structural mechanism of a drug-binding process involving a large conformational change of the protein target

[1]  Steven K. Albanese,et al.  Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance , 2021, Proceedings of the National Academy of Sciences.

[2]  Trayder Thomas,et al.  Diversity of Long-Lived Intermediates along the Binding Pathway of Imatinib to Abl Kinase Revealed by MD Simulations. , 2020, Journal of chemical theory and computation.

[3]  C. Kalodimos,et al.  Conformational states dynamically populated by a kinase determine its function , 2020, Science.

[4]  J. P. Grossman,et al.  The u-series: A separable decomposition for electrostatics computation with improved accuracy. , 2019, The Journal of chemical physics.

[5]  Jie Zheng,et al.  Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments , 2019, Nature Methods.

[6]  Lydia E Kavraki,et al.  Quantitative comparison of adaptive sampling methods for protein dynamics. , 2018, The Journal of chemical physics.

[7]  T. Smithgall,et al.  The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation , 2018, Science Signaling.

[8]  Paul Robustelli,et al.  Developing a molecular dynamics force field for both folded and disordered protein states , 2018, Proceedings of the National Academy of Sciences.

[9]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[10]  C. Kalodimos,et al.  Gleevec Can Act as an Allosteric Activator of ABL Kinase , 2018 .

[11]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[12]  F. Gervasio,et al.  Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase , 2016, Scientific Reports.

[13]  R. Roskoski.  Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.

[14]  Gregory R Bowman,et al.  FAST Conformational Searches by Balancing Exploration/Exploitation Trade-Offs. , 2015, Journal of chemical theory and computation.

[15]  B. Halle,et al.  How amide hydrogens exchange in native proteins , 2015, Proceedings of the National Academy of Sciences.

[16]  John R Engen,et al.  Analytical Aspects of Hydrogen Exchange Mass Spectrometry. , 2015, Annual review of analytical chemistry.

[17]  Ville R. I. Kaila,et al.  Conformational processing of oncogenic v-Src kinase by the molecular chaperone Hsp90 , 2015, Proceedings of the National Academy of Sciences.

[18]  D. Kern,et al.  Energetic dissection of Gleevec’s selectivity towards human tyrosine kinases , 2014, Nature Structural &Molecular Biology.

[19]  Harel Weinstein,et al.  NbIT - A New Information Theory-Based Analysis of Allosteric Mechanisms Reveals Residues that Underlie Function in the Leucine Transporter LeuT , 2014, PLoS Comput. Biol..

[20]  Kenneth M. Mackenzie,et al.  Accurate and efficient integration for molecular dynamics simulations at constant temperature and pressure. , 2013, The Journal of chemical physics.

[21]  Albert C. Pan,et al.  Transitions to catalytically inactive conformations in EGFR kinase , 2013, Proceedings of the National Academy of Sciences.

[22]  Susan Lindquist,et al.  Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition , 2012, Cell.

[23]  G. de Fabritiis,et al.  Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations , 2011, Proceedings of the National Academy of Sciences.

[24]  S. Berkowitz,et al.  The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. , 2011, Journal of pharmaceutical sciences.

[25]  Eric T. Kim,et al.  How does a drug molecule find its target binding site? , 2011, Journal of the American Chemical Society.

[26]  Francesco L. Gervasio,et al.  Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib , 2011, Biomolecular NMR assignments.

[27]  Susan S. Taylor,et al.  Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.

[28]  Susan S. Taylor,et al.  Defining the Conserved Internal Architecture of a Protein Kinase , 2010, Biochimica et biophysica acta.

[29]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[30]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[31]  John R. Engen,et al.  Conformational disturbance in Abl kinase upon mutation and deregulation , 2009, Proceedings of the National Academy of Sciences.

[32]  R. Dror,et al.  A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.

[33]  John R Engen,et al.  High-speed and high-resolution UPLC separation at zero degrees Celsius. , 2008, Analytical chemistry.

[34]  W. Jahnke,et al.  Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib , 2008, Biomolecular NMR assignments.

[35]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[36]  Sungjoon Kim,et al.  Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.

[37]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[38]  Daniel K. Treiber,et al.  Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. , 2006, Cancer research.

[39]  T. Wales,et al.  Hydrogen exchange mass spectrometry for the analysis of protein dynamics. , 2006, Mass spectrometry reviews.

[40]  J. Kuriyan,et al.  High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases , 2005, Protein science : a publication of the Protein Society.

[41]  A. F. Neuwald,et al.  Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? , 2005, Journal of molecular biology.

[42]  François Stricher,et al.  The FoldX web server: an online force field , 2005, Nucleic Acids Res..

[43]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[44]  Zoltán Varga,et al.  Acid-base profiling of imatinib (gleevec) and its fragments. , 2005, Journal of medicinal chemistry.

[45]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[46]  I. Iakovidis,et al.  The road ahead. , 2004, Studies in health technology and informatics.

[47]  J. Onuchic,et al.  Nonlinear elasticity, proteinquakes, and the energy landscapes of functional transitions in proteins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[49]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[50]  G. Superti-Furga,et al.  A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.

[51]  H. Kantarjian,et al.  Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. , 2003, Blood.

[52]  G. Daley,et al.  Novel retroviral vectors to facilitate expression screens in mammalian cells. , 2002, Nucleic acids research.

[53]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[54]  R. Samudrala.  Faculty Opinions recommendation of Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002 .

[55]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[56]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[57]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[58]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[59]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[60]  Maria Deak,et al.  Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C‐terminal residues of PKA , 2000, The EMBO journal.

[61]  M Rance,et al.  Sensitivity improvement of transverse relaxation-optimized spectroscopy. , 1999, Journal of magnetic resonance.

[62]  G. Zhu,et al.  Gradient and sensitivity enhancement of 2D TROSY with water flip-back, 3D NOESY-TROSY and TOCSY-TROSY experiments , 1999, Journal of biomolecular NMR.

[63]  J. Weigelt.  Single Scan, Sensitivity- and Gradient-Enhanced TROSY for Multidimensional NMR Experiments , 1998 .

[64]  M. Czisch,et al.  Sensitivity enhancement in the TROSY experiment. , 1998, Journal of magnetic resonance.

[65]  K Wüthrich,et al.  Single Transition-to-single Transition Polarization Transfer (ST2-PT) in [15N,1H]-TROSY , 1998, Journal of biomolecular NMR.

[66]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[67]  D. Kassel,et al.  Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. , 1995, Biochemistry.

[68]  L. Cantley,et al.  Recognition and specificity in protein tyrosine kinase-mediated signalling. , 1995, Trends in biochemical sciences.

[69]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[70]  Mark E. Tuckerman,et al.  Reversible multiple time scale molecular dynamics , 1992 .

[71]  R. R. Ernst,et al.  Reduction of multiplet complexity in COSY-type NMR spectra: The bilinear and planar COSY experiments , 1991 .

[72]  J. Dixon,et al.  Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[73]  E. Reddy,et al.  Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Hoover,et al.  Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.